Melanotan II peptide

Melanotan II peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Ac-Nle-cyclo(DHfRWK)-NH2, f=D-Phe

Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-NH2

7

98.9%

C₅₀H₆₉N₁₅O₉

1024.18

Synthetic

Powder

CAS NO.: 121062-08-6. Melanotan 2 (also referred to as Melanotan II) is a synthetically produced variant of a peptide hormone naturally produced in the body that stimulates melanogenesis, a process responsible for pigmentation of the skin. This peptide hormone, called alpha-Melanocyte stimulating hormone or MSH, activates certain melanocortin receptors in the process of exerting its effects. Indeed, MSH also exerts potent influence over lipid metabolism, appetite, and sexual libido via these melanocortin receptors. As a result, Melanotan 2 has been shown in studies to exhibit appetite suppressant, lipolytic, and libido-enhancing effects in addition to promoting skin tanning. Melanotan 2 has been researched extensively for use in protecting against the harmful effects of ultraviolet radiation from sunlight due to its melanogenesis-stimulating properties.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.